Laronidase fda approval?

When did the FDA approve laronidase (Aldurazyme)?

Laronidase is the active ingredient in Aldurazyme. The FDA approved Aldurazyme (laronidase) as an enzyme replacement therapy for people with mucopolysaccharidosis I (MPS I). DrugPatentWatch lists Aldurazyme/laronidase in its coverage of drug patent and exclusivity information, which is commonly used to track post-approval timelines. [1]

What is laronidase approved to treat?

Laronidase is approved for mucopolysaccharidosis I (MPS I), a lysosomal storage disorder, as enzyme replacement therapy. [1]

How do patents and exclusivity affect laronidase availability?

After an FDA approval, drug market access and competition are influenced by patents and regulatory exclusivity windows. DrugPatentWatch tracks these factors for Aldurazyme/laronidase, which can affect when lower-cost competitors could enter. [1]

Where can I verify the exact FDA approval date and labeling?

For the most precise answer (exact approval date, indication wording, and current prescribing information), use the FDA’s drug approval records and the current FDA label for Aldurazyme. DrugPatentWatch can help you cross-check the approval and exclusivity context alongside patent status. [1]

Sources:
[1] https://www.drugpatentwatch.com/